DR. EVE E. SLATER, M.D.
Medical Practice at Kenilworth Dr, Short Hills, NJ
License number
New Jersey 148853
Category
Medical Practice
Type
Specialist
Address
Address
19 Kenilworth Dr, Short Hills, NJ 07078
Phone
(973) 467-9630
(973) 467-4610 (Fax)
(973) 467-4610 (Fax)
Professional information
Dr. Eve E Slater, Short Hills NJ - MD (Doctor of Medicine)
Specialties:
Cardiology
Address:
19 Kenilworth Dr, Short Hills 07078
(973) 467-9630 (Phone), (973) 467-4610 (Fax)
(973) 467-9630 (Phone), (973) 467-4610 (Fax)
Procedures:
Cardiac Catheterization (incl. Coronary Angiography), Chest CT (incl. Heart and Lungs), Tilt Testing or Cardiac Event Monitors
Conditions:
Angina and Acute Coronary Syndrome, Aortic Aneurysm, Aortic Valve Disease, Arrhythmias (incl. Atrial Fibrillation), Cardiomyopathy, Congestive Heart Failure, Coronary Artery Disease (CAD), Endocarditis, Heart Attack (Acute Myocardial Infarction), Hyperlipidemia, Hypertension, Hypotension, Mitral Valve Disease, Pericardial Disease, Pulmonary Hypertension, Syncope, Tricuspid Valve Disease
Certifications:
Cardiovascular Disease, 1977, Internal Medicine, 1974
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Columbia University / College of Physicians And Surgeons
Graduated: 1971
Massachusetts General Hospital
Columbia University / College of Physicians And Surgeons
Graduated: 1971
Massachusetts General Hospital
Novel Phosphotyrosyl Protein Phosphatase
US Patent:
4710469, Dec 1, 1987
Filed:
May 2, 1986
Appl. No.:
6/858622
Inventors:
Eve E. Slater - Short Hills NJ
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
C12N 912
US Classification:
435194
Abstract:
A glycoprotein phosphotyrosyl protein phosphatase is isolated from human tissues, such as human placental membrane. Upon membrane solubilization and extraction of the enzyme it was subjected to chromatographic purification and isolation. The analytical and biological responses of the enzyme demonstrate that it is novel and readily distinguished from other enzymes previously isolated from similar tissues. The enzyme is a dephosphorylation enzyme of membrane phosphoprotein kinases, and as such has utility as an antidiabetic agent, an antiatherosclerosis agent or an antitumor agent since certain membrane receptor kinases involved in each such biological function involve a phosphorylation mechanism for cell transformation, metabolism and growth and which, when blocked by the instant enzyme, results in a suppression or alteration of the biological function.
Substituted 6H-7,8-Dihydrothiapyrano(3,2-D)-Pyrimidines As Hypoglycemic Agents
US Patent:
4978667, Dec 18, 1990
Filed:
Sep 12, 1988
Appl. No.:
7/242766
Inventors:
Richard Saperstein - Edison NJ
Richard L. Tolman - Warren NJ
Eve E. Slater - Short Hills NJ
Richard L. Tolman - Warren NJ
Eve E. Slater - Short Hills NJ
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
A61K 31505
US Classification:
514258
Abstract:
There are disclosed certain 2-alkyl-4-substituted 6H-7,8-dihydrothiapyrano[3,2-d]pyrimidines which have oral hypoglycermic activity and with such ability to lower blood sugar are useful in the treatment of type II diabetes and/or obesity with associated insulin resistance. Processes for the preparation of such compounds and compositions containing such compounds as the active ingredient thereof are also disclosed.